BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35779846)

  • 1. Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic.
    Kocijan R; Stockinger T; Haschka J; Reichardt B; Resch H; Zwerina J; Behanova M
    Bone; 2022 Sep; 162():116477. PubMed ID: 35779846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
    Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
    Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
    Cromer SJ; D'Silva KM; Yu EW; Landon J; Desai RJ; Kim SC
    J Gen Intern Med; 2022 Jun; 37(8):1917-1924. PubMed ID: 34100235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece.
    Yavropoulou MP; Makras P; Athanasakis K; Bournia VK; Mathioudakis K; Tsolakidis A; Kassi E; Kaltsas G; Mitrou P; Sfikakis PP
    Arch Osteoporos; 2022 Jun; 17(1):86. PubMed ID: 35761110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
    Kamata Y; Minota S
    Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
    Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
    Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P
    Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
    Kristensen PK; Ehrenstein V; Shetty N; Pedersen AB
    Osteoporos Int; 2019 Sep; 30(9):1817-1825. PubMed ID: 31263921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.
    De Vincentis S; Domenici D; Ansaloni A; Boselli G; D'Angelo G; Russo A; Taliani E; Rochira V; Simoni M; Madeo B
    J Endocrinol Invest; 2022 Oct; 45(10):1887-1897. PubMed ID: 35590044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.
    Imel EA; Starzyk K; Gliklich R; Weiss RJ; Wang Y; Williams SA
    Osteoporos Int; 2020 Dec; 31(12):2413-2424. PubMed ID: 32696118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis.
    Ebina K; Hashimoto J; Kashii M; Hirao M; Kaneshiro S; Noguchi T; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2017 Jan; 35(1):91-98. PubMed ID: 26762133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia.
    Chandran M; Hao Y; Kwee AK; Cheen MHH; Chin YA; Ng VYT
    Osteoporos Int; 2022 Jan; 33(1):251-261. PubMed ID: 34417842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.